Observational studyBritish journal of clinical pharmacology2021
Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study.
Observational study in British journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study.Molecular psychiatry · 2021Pooled it
- Age influences blood cell-based immune deregulation antibody response and unfavorable clinical outcomes in COVID-19 patients.Scientific reports · 2025Article
- Article
- Applying Natural Language Processing to Textual Data From Clinical Data Warehouses: Systematic Review.JMIR medical informatics · 2023Review
- Comparison of COVID-19 Preprint and Peer-Reviewed Versions of Studies on Therapies for Critically Ill Patients.Journal of intensive care medicine · 2023Article
- Medications Modulating the Acid Sphingomyelinase/Ceramide System and 28-Day Mortality among Patients with SARS-CoV-2: An Observational Study.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Comprehensive evaluation of six interventions for hospitalized patients with COVID-19: A propensity score matching study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Treatment mechanism of immune triad from the repurposing drug against COVID-19.Translational medicine of aging · 2023Review
- Risk of Death in Individuals Hospitalized for COVID-19 With and Without Psychiatric Disorders: An Observational Multicenter Study in France.Biological psychiatry global open science · 2023Article
- Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19.Journal of clinical medicine · 2022Article
- [Impact of Staphylococcus aureus bacteremia in COVID-19 patients].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Article
- Efficacy and safety of corticosteroid regimens for the treatment of hospitalized COVID-19 patients: a meta-analysis.Future virology · 2022Review
- Association between benzodiazepine receptor agonist use and mortality in patients hospitalised for COVID-19: a multicentre observational study.Epidemiology and psychiatric sciences · 2022Observational
- Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study.Translational psychiatry · 2022Article
- The acid sphingomyelinase/ceramide system in COVID-19.Molecular psychiatry · 2022Review
- Hydroxyzine Use and Mortality in Patients Hospitalized for COVID-19: A Multicenter Observational Study.Journal of clinical medicine · 2021Article
- Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: An Observational Multicenter Study.Clinical pharmacology and therapeutics · 2021Observational
- Dexamethasone in COVID-19: Should we consider a "golden hour" practice?International journal of clinical practice · 2021Article
- Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study.British journal of clinical pharmacology · 2021Observational
- Observational Study of Chlorpromazine in Hospitalized Patients with COVID-19.Clinical drug investigation · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo examine the association between dexamethasone use and mortality among patients hospitalized for COVID-19.
methodsWe examined the association between dexamethasone use and mortality at AP-HP Greater Paris University hospitals. Study baseline was defined as the date of hospital admission. The primary endpoint was time to death. We compared this endpoint between patients who received dexamethasone and those who did not in time-to-event analyses adjusted for patient characteristics (such as age, sex and comorbidity) and clinical and biological markers of clinical severity of COVID-19, and stratified by the need for respiratory support, i.e. mechanical ventilation or oxygen. The primary analysis was a multivariable Cox regression model.
resultsOf 12 217 adult patients hospitalized with a positive COVID-19 reverse transcriptase-polymerase chain reaction test, 171 (1.4%) received dexamethasone orally or by intravenous perfusion during the visit. Among patients who required respiratory support, the end-point occurred in 10/63 (15.9%) patients who received dexamethasone and 298/1129 (26.4%) patients who did not. In this group, there was a significant association between dexamethasone use and reduced mortality in the primary analysis (hazard ratio, 0.46; 95% confidence interval 0.22-0.96, P = .039). Among patients who did not require respiratory support, there was no significant association between dexamethasone use and the endpoint.
conclusionsIn this multicentre observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.